MAX KELLEHER
COO, Generis, London, United Kingdom

Abstract

Leaders from BioNTech, Bayer, Iperion – a Deloitte business, and Beczek.COM came together in December 2022 to discuss the critical next steps for the life sciences industry in its transition toward a data-driven future. Max Kelleher, COO of Generis, chaired the proceedings.

THE STATUS QUO
The panel began by reflecting on the current state of data management, particularly around regulatory data, in Life Sciences – and where this is all moving.

Frits Stulp of Iperion – a Deloitte business, noted that the visibility of the Life Sciences industry has been elevated tremendously over the last three years, due to COVID and the direct and immediate value of emerging medicine to quality of life for many people. However the pandemic also shone a light on archaic registration processes which today still involve the exchange of PDFs. Stakeholders across the industry have begun to see that there is a better way to manage this, he said.

WHO WILL DRIVE DATA QUALITY?
As processes become more data driven, some organisational concerns are emerging around who will drive all of the necessary rigour around data quality? Will that, and should that, be the regulators -via compliance?

Frits suggested that a joint innovation initiative would be most productive. Regulators are not necessarily there to drive innovation, but do need to pave ...